Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

por Kaira, Kyoichi, Kuji, Ichiei, Kagamu, Hiroshi
Publicado 2021

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma

por Kaira, Kyoichi, Imai, Hisao, Kagamu, Hiroshi
Publicado 2021

Advanced Research on Immune Checkpoint Inhibitor Therapy

por Imai, Hisao, Kaira, Kyoichi, Kagamu, Hiroshi
Publicado 2022

Bevacizumab-induced Aortic Arterial Thrombosis

por Suzuki, Kazuo, Yanagimura, Takahiro, Ohashi, Kazumasa, Kagamu, Hiroshi, Takada, Toshinori
Publicado 2018

Spontaneous aspiration of a long tree twig as foreign body

por Hashimoto, Kosuke, Kaira, Kyoichi, Kobayashi, Kunihiko, Murayama, Yoshitake, Kagamu, Hiroshi
Publicado 2019

Osimertinib induced cardiomyopathy: A case report

por Shinomiya, Shun, Kaira, Kyoichi, Yamaguchi, Ou, Ishikawa, Keitaro, Kagamu, Hiroshi
Publicado 2020

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma

por Kaira, Kyoichi, Imai, Hisao, Yamaguchi, Ou, Mouri, Atsuto, Kagamu, Hiroshi
Publicado 2021

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

por Kaira, Kyoichi, Imai, Hisao, Mouri, Atsuto, Yamaguchi, Ou, Kagamu, Hiroshi
Publicado 2021

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0...

por Kaira, Kyoichi, Mouri, Atsuto, Kato, Shingo, Yoshimura, Kenichi, Kagamu, Hiroshi, Kobayashi, Kunihiko
Publicado 2020

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously tre...

por Mouri, Atsuto, Kaira, Kyoichi, Shiono, Ayako, Yamaguchi, Ou, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi
Publicado 2019

Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report

por Kurihara, Susumu, Oikawa, Yoichi, Nakajima, Ritsuko, Satomura, Atsushi, Tanaka, Ryuhei, Kagamu, Hiroshi, Shimada, Akira
Publicado 2020

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features

por Shiono, Ayako, Fujino, Takashi, Kaira, Kyoichi, Kato, Tomomi, Yasuda, Masanori, Kobayashi, Kunihiko, Kagamu, Hiroshi
Publicado 2020

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

por Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Chocarro, Luisa, Vera, Ruth, Escors, David, Kagamu, Hiroshi, Kochan, Grazyna
Publicado 2020

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report

por Kobayashi, Kunihiko, Kaira, Kyoichi, Iemura, Hidetoshi, Shinomiya, Shun, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Nishihara, Fuyumi, Kagamu, Hiroshi
Publicado 2021

Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade

por Takeda, Masashi, Kashima, Soki, Fuchigami, Yasushi, Yoshino, Takayuki, Kataoka, Tatsuki R., Yamasaki, Toshinari, Kagamu, Hiroshi, Kobayashi, Takashi, Akamatsu, Shusuke
Publicado 2022

DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations

por Nozaki, Koichiro, Kagamu, Hiroshi, Shoji, Satoshi, Igarashi, Natsue, Ohtsubo, Aya, Okajima, Masaaki, Miura, Satoru, Watanabe, Satoshi, Yoshizawa, Hirohisa, Narita, Ichiei
Publicado 2014

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

por Hashimoto, Kosuke, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei
Publicado 2020

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

por Yamaguchi, Ou, Kaira, Kyoichi, Hashimoto, Kosuke, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei
Publicado 2020

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

por Kaira, Kyoichi, Kobayashi, Kunihiko, Shiono, Ayako, Yamaguchi, Ou, Hashimoto, Kosuke, Mouri, Atsuto, Shinomiya, Shun, Miura, Yu, Imai, Hisao, Kagamu, Hiroshi
Publicado 2021

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs

por Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kousuke, Miura, Yu, Shiono, Ayako, Shinomiya, Shun, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Publicado 2021